Apparently the 17.2 is suppose to be bioequivalent to the 36 in trial, not sure why the weight loss % reported is different tho
Methods Qualitative, individual, semi-structured interviews were conducted in nine participants who were prescribed GLP-1 receptor agonists for the treatment of obesity and/or T2D
Further, they had no previous history of depression, use of antidepressants in the previous year, or type 1 diabetes
Advances in oral peptide delivery technologies and combination molecules targeting GLP-1, GIP, and glucagon receptors are expected to enhance therapeutic efficacy while reducing dependence on injectable formulations
Williams, 44, said that she made the decision after trying just about every other avenue